RU2325159C2 - Применение производных изохинолина для лечения рака и заболеваний, связанных с киназой мар - Google Patents
Применение производных изохинолина для лечения рака и заболеваний, связанных с киназой мар Download PDFInfo
- Publication number
- RU2325159C2 RU2325159C2 RU2005131168/04A RU2005131168A RU2325159C2 RU 2325159 C2 RU2325159 C2 RU 2325159C2 RU 2005131168/04 A RU2005131168/04 A RU 2005131168/04A RU 2005131168 A RU2005131168 A RU 2005131168A RU 2325159 C2 RU2325159 C2 RU 2325159C2
- Authority
- RU
- Russia
- Prior art keywords
- ness
- phenyl
- alkyl
- substituted
- halogen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract 5
- 201000011510 cancer Diseases 0.000 title claims abstract 5
- 201000010099 disease Diseases 0.000 title claims abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract 5
- 108091000080 Phosphotransferase Proteins 0.000 title claims 2
- 102000020233 phosphotransferase Human genes 0.000 title claims 2
- 238000000034 method Methods 0.000 claims abstract 23
- 201000001441 melanoma Diseases 0.000 claims abstract 14
- 102000009929 raf Kinases Human genes 0.000 claims abstract 13
- 108010077182 raf Kinases Proteins 0.000 claims abstract 13
- 150000001875 compounds Chemical class 0.000 claims abstract 7
- 102000043136 MAP kinase family Human genes 0.000 claims abstract 4
- 108091054455 MAP kinase family Proteins 0.000 claims abstract 4
- 230000035772 mutation Effects 0.000 claims abstract 4
- 239000003814 drug Substances 0.000 claims abstract 3
- -1 hydroxy, hydroxy Chemical group 0.000 claims 40
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 27
- 229910052736 halogen Inorganic materials 0.000 claims 24
- 150000002367 halogens Chemical group 0.000 claims 18
- 125000003282 alkyl amino group Chemical group 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 14
- 125000002947 alkylene group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 8
- 125000004414 alkyl thio group Chemical group 0.000 claims 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 8
- 125000001589 carboacyl group Chemical group 0.000 claims 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 6
- 241000534944 Thia Species 0.000 claims 5
- 150000001204 N-oxides Chemical class 0.000 claims 4
- 125000004423 acyloxy group Chemical group 0.000 claims 4
- 125000005236 alkanoylamino group Chemical group 0.000 claims 4
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 4
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 4
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000002018 overexpression Effects 0.000 claims 3
- 230000019491 signal transduction Effects 0.000 claims 3
- 230000011664 signaling Effects 0.000 claims 3
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims 2
- 230000003213 activating effect Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 125000005156 substituted alkylene group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 230000008054 signal transmission Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45362403P | 2003-03-11 | 2003-03-11 | |
| US60/453,624 | 2003-03-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005131168A RU2005131168A (ru) | 2006-05-27 |
| RU2325159C2 true RU2325159C2 (ru) | 2008-05-27 |
Family
ID=32990797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131168/04A RU2325159C2 (ru) | 2003-03-11 | 2004-03-10 | Применение производных изохинолина для лечения рака и заболеваний, связанных с киназой мар |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1603566B1 (https=) |
| JP (1) | JP2006519807A (https=) |
| KR (1) | KR20050108383A (https=) |
| CN (1) | CN1758910A (https=) |
| AT (1) | ATE421324T1 (https=) |
| AU (1) | AU2004218914A1 (https=) |
| BR (1) | BRPI0408257A (https=) |
| CA (1) | CA2518530A1 (https=) |
| DE (1) | DE602004019193D1 (https=) |
| ES (1) | ES2318276T3 (https=) |
| HR (1) | HRP20050788A2 (https=) |
| IS (1) | IS8064A (https=) |
| MA (1) | MA27724A1 (https=) |
| MX (1) | MXPA05009687A (https=) |
| NO (1) | NO20054647L (https=) |
| PL (1) | PL1603566T3 (https=) |
| PT (1) | PT1603566E (https=) |
| RU (1) | RU2325159C2 (https=) |
| TN (1) | TNSN05223A1 (https=) |
| TW (1) | TW200501955A (https=) |
| WO (1) | WO2004080464A1 (https=) |
| ZA (1) | ZA200506571B (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05012377A (es) | 2003-05-15 | 2006-05-25 | Arqule Inc | Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38. |
| AR045944A1 (es) * | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| WO2006010082A1 (en) | 2004-07-08 | 2006-01-26 | Arqule, Inc. | 1,4-disubstituted naphtalenes as inhibitors of p38 map kinase |
| JP2008517064A (ja) | 2004-10-19 | 2008-05-22 | アークル インコーポレイテッド | Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成 |
| CN101160131A (zh) * | 2005-02-25 | 2008-04-09 | 诺瓦提斯公司 | Bcr-abl和raf抑制剂的药物组合产品 |
| JP5049970B2 (ja) * | 2005-07-26 | 2012-10-17 | サノフイ | Ｒｈｏ−キナーゼ阻害剤としてのシクロヘキシルアミンイソキノロン誘導体 |
| US8318941B2 (en) | 2006-07-06 | 2012-11-27 | Bristol-Myers Squibb Company | Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| CA2639416C (en) * | 2007-09-11 | 2019-12-31 | F. Hoffmann-La Roche Ag | Diagnostic test for susceptibility to b-raf kinase inhibitors |
| EP3284494A1 (en) | 2009-07-30 | 2018-02-21 | Tandem Diabetes Care, Inc. | Portable infusion pump system |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| US9056855B2 (en) * | 2010-10-28 | 2015-06-16 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CN103435430B (zh) * | 2013-08-08 | 2015-02-18 | 四川大学 | 一种还原酰胺类化合物的方法 |
| KR102119943B1 (ko) | 2018-05-23 | 2020-06-05 | 주식회사 포스코 | 시편배치유닛 및 이를 포함하는 도장밀착성 실험장치 |
| US20210275516A1 (en) * | 2018-07-02 | 2021-09-09 | Ecole Polytechnique Federale De Lausanne (Epfl) | Lactate enhancing compounds and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2000102667A (ru) * | 1997-07-11 | 2001-10-20 | Новартис Аг | Производные пиридина |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW544448B (en) * | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| ATE459616T1 (de) * | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| GT200000158A (es) * | 1999-09-28 | 2002-03-16 | Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis. | |
| PT1254138E (pt) * | 2000-02-09 | 2005-09-30 | Novartis Ag | Derivados de piridina que inibem a angiogenese e/ou o receptor de tirosina cinase do vegf |
| US20030078271A1 (en) * | 2001-01-31 | 2003-04-24 | Blackburn Thomas P. | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| DE60239097D1 (de) * | 2001-03-02 | 2011-03-17 | Gpc Biotech Ag | Drei-hybrid-assaysystem |
| MXPA04005561A (es) * | 2001-12-21 | 2004-12-06 | Bayer Pharmaceuticals Corp | Terapias de combinacion anti-angiogenesis que comprenden derivados de piridazina o piridina. |
| US7220775B2 (en) * | 2002-08-07 | 2007-05-22 | H. Lundbeck A/S | Compound useful for the treatment of neuropathic pain |
-
2004
- 2004-03-10 AT AT04718960T patent/ATE421324T1/de active
- 2004-03-10 RU RU2005131168/04A patent/RU2325159C2/ru not_active IP Right Cessation
- 2004-03-10 BR BRPI0408257-5A patent/BRPI0408257A/pt not_active IP Right Cessation
- 2004-03-10 CA CA002518530A patent/CA2518530A1/en not_active Abandoned
- 2004-03-10 AU AU2004218914A patent/AU2004218914A1/en not_active Abandoned
- 2004-03-10 DE DE602004019193T patent/DE602004019193D1/de not_active Expired - Lifetime
- 2004-03-10 PT PT04718960T patent/PT1603566E/pt unknown
- 2004-03-10 JP JP2006504625A patent/JP2006519807A/ja active Pending
- 2004-03-10 EP EP04718960A patent/EP1603566B1/en not_active Expired - Lifetime
- 2004-03-10 MX MXPA05009687A patent/MXPA05009687A/es active IP Right Grant
- 2004-03-10 TW TW093106341A patent/TW200501955A/zh unknown
- 2004-03-10 CN CNA2004800065706A patent/CN1758910A/zh active Pending
- 2004-03-10 HR HR20050788A patent/HRP20050788A2/xx not_active Application Discontinuation
- 2004-03-10 WO PCT/EP2004/002460 patent/WO2004080464A1/en not_active Ceased
- 2004-03-10 KR KR1020057016936A patent/KR20050108383A/ko not_active Ceased
- 2004-03-10 PL PL04718960T patent/PL1603566T3/pl unknown
- 2004-03-10 ES ES04718960T patent/ES2318276T3/es not_active Expired - Lifetime
-
2005
- 2005-08-17 ZA ZA200506571A patent/ZA200506571B/en unknown
- 2005-09-09 TN TNP2005000223A patent/TNSN05223A1/en unknown
- 2005-09-23 MA MA28511A patent/MA27724A1/fr unknown
- 2005-10-10 IS IS8064A patent/IS8064A/is unknown
- 2005-10-10 NO NO20054647A patent/NO20054647L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2000102667A (ru) * | 1997-07-11 | 2001-10-20 | Новартис Аг | Производные пиридина |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006519807A (ja) | 2006-08-31 |
| CN1758910A (zh) | 2006-04-12 |
| NO20054647D0 (no) | 2005-10-10 |
| MA27724A1 (fr) | 2006-01-02 |
| PT1603566E (pt) | 2009-04-27 |
| MXPA05009687A (es) | 2005-10-20 |
| WO2004080464A1 (en) | 2004-09-23 |
| EP1603566B1 (en) | 2009-01-21 |
| AU2004218914A1 (en) | 2004-09-23 |
| TNSN05223A1 (en) | 2007-06-11 |
| DE602004019193D1 (de) | 2009-03-12 |
| ATE421324T1 (de) | 2009-02-15 |
| HRP20050788A2 (en) | 2006-12-31 |
| IS8064A (is) | 2005-10-10 |
| CA2518530A1 (en) | 2004-09-23 |
| PL1603566T3 (pl) | 2009-07-31 |
| TW200501955A (en) | 2005-01-16 |
| ZA200506571B (en) | 2006-07-26 |
| ES2318276T3 (es) | 2009-05-01 |
| NO20054647L (no) | 2005-12-09 |
| BRPI0408257A (pt) | 2006-03-07 |
| RU2005131168A (ru) | 2006-05-27 |
| EP1603566A1 (en) | 2005-12-14 |
| KR20050108383A (ko) | 2005-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2325159C2 (ru) | Применение производных изохинолина для лечения рака и заболеваний, связанных с киназой мар | |
| Sarnella et al. | Inhibition of carbonic anhydrases IX/XII by SLC-0111 boosts cisplatin effects in hampering head and neck squamous carcinoma cell growth and invasion | |
| EP1339458B1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| Swanson et al. | Anti-cancer therapy: targeting the mevalonate pathway | |
| RU2006113697A (ru) | 1,4-дизамещенные производные изохинолина в качестве ингибиторов raf-киназы, предназначенных для лечения пролиферативных заболеваний | |
| RU2508110C2 (ru) | КОМБИНАЦИЯ (А) ИНГИБИТОРА ФОСФОИНОЗИТ-3-КИНАЗЫ И (Б) МОДУЛЯТОРА ПУТИ Ras/Raf/Mek | |
| RU2456983C2 (ru) | Комбинация ингибиторов iap и flt3 | |
| RU2717570C2 (ru) | Синергистические комбинации ауристана | |
| ES2600304T3 (es) | Tratamiento de tumores sólidos de riñón con un derivado de rapamicina | |
| RU2017145026A (ru) | Соединение, ингибирующее brk | |
| Huang et al. | Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib | |
| KR20090082221A (ko) | 유기 화합물 | |
| EP3938354A2 (en) | Compositions and methods for treating cancer | |
| ZA200404225B (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers. | |
| WO2001047507A2 (en) | Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound | |
| JP2022145800A (ja) | 静止細胞標的化およびｅｇｆｒ阻害剤を用いた新生物の処置のための組み合わせ | |
| ATE390421T1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| IL202014A (en) | A synergistic combination of cancer treatment | |
| RU2009147819A (ru) | Комбинация ингибиторов снк и parp для лечения злокачественных новообразований | |
| WO2013087964A1 (es) | Uso de agentes modificadores del ambiente peritumoral para el tratamiento del cáncer | |
| RU2423980C2 (ru) | Комбинации, включающие эпотилоны и ингибиторы протеинтирозинкиназы и их фармацевтическое применение | |
| RU2006100484A (ru) | Соединения, обладающие ингибирующей активностью в отношении фосфатидилинозит-3-киназы, фармацевтическая композиция, способ определения эффективности этих соединений, способ лечения нарушений (варианты) и способ изменения передачи сигнала в клетках | |
| Hsueh et al. | MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors | |
| JPWO2016167236A1 (ja) | Ｍｄｍ２阻害剤とｂｔｋ阻害剤との併用治療法 | |
| JP2026506429A (ja) | Ｍｔａ協同的ｐｒｍｔ５阻害薬を使用した癌治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20120311 |